AT ASCO
Gilead Sciences and Yescarta®
By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology and its FDA approved therapy Yescarta. At the ASCO 2019 two new analyses were presented from the ZUMA-1 clinical trial of Yescarta® in adult patients with relapsed or . . .
This content is for paid subscribers.
Today’s Highlights
June 6, 2019
